The Naarden, Netherlands-based venture capital company, BioGeneration Ventures (BGV), has raised €82m at the final close of its third fund, BGV III, to provide seed investments to European biotech companies involved in developing therapeutics, medical devices and diagnostics, particularly those based in the Benelux countries – Belgium, the Netherlands and Luxembourg – and in Germany.
The fund is four times larger than previous funds raised by BGV (€17m in 2006 and €15m in 2012), and is now one of the largest funds ever raised for